SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Miyako Kishimoto, Mitsuhiko Noda, Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study, Clinical Drug Investigation, 2015, 35, 2, 141

    CrossRef

  2. 2
    Daisuke Yabe, Akira Kuroe, Koin Watanabe, Masahiro Iwasaki, Akihiro Hamasaki, Yoshiyuki Hamamoto, Norio Harada, Shunsuke Yamane, Soushou Lee, Kenta Murotani, Carolyn F. Deacon, Jens J. Holst, Tsutomu Hirano, Nobuya Inagaki, Takeshi Kurose, Yutaka Seino, Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients, Journal of Diabetes and its Complications, 2015, 29, 3, 413

    CrossRef

  3. 3
    Hiroaki Ueno, Wakaba Tsuchimochi, Hong-Wei Wang, Eiichiro Yamashita, Chikako Tsubouchi, Kazuhiro Nagamine, Hideyuki Sakoda, Masamitsu Nakazato, Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study, Diabetes Therapy, 2015, 6, 2, 187

    CrossRef

  4. 4
    Takahiro Watanabe, Yoshifumi Tamura, Saori Kakehi, Takashi Funayama, Amalia Gastaldelli, Kageumi Takeno, Minako Kawaguchi, Risako Yamamoto, Fumihiko Sato, Shin-ichi Ikeda, Hikari Taka, Tsutomu Fujimura, Yoshio Fujitani, Ryuzo Kawamori, Hirotaka Watada, Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study, Journal of Diabetes Investigation, 2015, 6, 2
  5. 5
    Yukiko Onishi, Elisabeth Niemoeller, Yukio Ikeda, Hiroki Takagi, Daisuke Yabe, Yutaka Seino, Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S, Journal of Diabetes Investigation, 2015, 6, 2
  6. 6
    Young Min Cho, Incretin physiology and pathophysiology from an Asian perspective, Journal of Diabetes Investigation, 2015, 6, 4
  7. 7
    Yutaka Seino, Daisuke Yabe, Akane Takami, Elisabeth Niemoeller, Hiroki Takagi, Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan, Journal of Diabetes and its Complications, 2015,

    CrossRef

  8. 8
    Nobuya Inagaki, Hitoshi Onouchi, Hideaki Maezawa, Shingo Kuroda, Kohei Kaku, Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study, The Lancet Diabetes & Endocrinology, 2015, 3, 3, 191

    CrossRef

  9. 9
    Daisuke Yabe, Yutaka Seino, Mitsuo Fukushima, Susumu Seino, β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians, Current Diabetes Reports, 2015, 15, 6

    CrossRef

  10. 10
    Yutaka Seino, Daisuke Yabe, Alogliptin for the treatment of Type 2 diabetes, Expert Review of Endocrinology & Metabolism, 2014, 9, 6, 547

    CrossRef

  11. 11
    Daisuke Yabe, Yutaka Seino, Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes, Expert Review of Endocrinology & Metabolism, 2014, 9, 6, 659

    CrossRef

  12. 12
    Atsushi Mikada, Takuma Narita, Hiroki Yokoyama, Risa Yamashita, Yohei Horikawa, Katsushi Tsukiyama, Yuichiro Yamada, Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. “The MASTER randomized, controlled trial”, Diabetes Research and Clinical Practice, 2014, 106, 3, 538

    CrossRef

  13. 13
    Hiroaki Ueno, Masanari Mizuta, Tomomi Shiiya, Wakaba Tsuchimochi, Kenji Noma, Noboru Nakashima, Mitsuteru Fujihara, Masamitsu Nakazato, Exploratory Trial of Intranasal Administration of Glucagon-Like Peptide-1 in Japanese Patients With Type 2 Diabetes: Figure 1, Diabetes Care, 2014, 37, 7, 2024

    CrossRef

  14. 14
    Y. Seino, A. Takami, G. Boka, E. Niemoeller, D. Raccah, Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin, Diabetes, Obesity and Metabolism, 2014, 16, 8
  15. 15
    J. Vora, Combining Incretin-Based Therapies With Insulin: Realizing the potential in type 2 diabetes, Diabetes Care, 2013, 36, Supplement_2, S226

    CrossRef

  16. 16
    Daisuke Yabe, Mariyo Rokutan, Yoshiyuki Miura, Izumi Komoto, Ryota Usui, Hitoshi Kuwata, Koin Watanabe, Takanori Hyo, Takeshi Kurose, Terumi Nagamatsu, Shinobu Shimizu, Jun Kawai, Masayuki Imamura, Yutaka Seino, Enhanced glucagon-like peptide-1 secretion in a patient with glucagonoma: Implications for glucagon-like peptide-1 secretion from pancreatic α cells in vivo, Diabetes Research and Clinical Practice, 2013, 102, 1, e1

    CrossRef

  17. 17
    Jie Shen, Zhi Chen, Chaofeng Chen, Xiao Zhu, Yajuan Han, Impact of incretin on early-phase insulin secretion and glucose excursion, Endocrine, 2013, 44, 2, 403

    CrossRef

  18. 18
    Atsushi Miyachi, Takayo Murase, Yuichiro Yamada, Takeshi Osonoi, Ken-ichi Harada, Quantitative Analytical Method for Determining the Levels of Gastric Inhibitory Polypeptides GIP1–42and GIP3–42in Human Plasma Using LC–MS/MS/MS, Journal of Proteome Research, 2013, 12, 6, 2690

    CrossRef

  19. 19
    Miyako Kishimoto, Mitsuhiko Noda, Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes, Diabetes Therapy, 2012, 3, 1

    CrossRef

  20. 20
    Y. Seino, Y. Miyata, S. Hiroi, M. Hirayama, K. Kaku, Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study, Diabetes, Obesity and Metabolism, 2012, 14, 10
  21. 21
    Yutaka Seino, Shinzo Hiroi, Masashi Hirayama, Kohei Kaku, Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study, Journal of Diabetes Investigation, 2012, 3, 6
  22. 22
    Kyuzi Kamoi, You Shinozaki, Kazuo Furukawa, Hideo Sasaki, Potential correlation between plasma total GIP levels and body mass index in Japanese patients with types 1 or 2 diabetes mellitus, Endocrine Journal, 2012, 59, 4, 353

    CrossRef

  23. 23
    Y. Seino, K. W. Min, E. Niemoeller, A. Takami, Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia), Diabetes, Obesity and Metabolism, 2012, 14, 10